Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Ending Cash Position : ¥1,416 Mil (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Ending Cash Position?

Shenzhenlubris Pharmaceuticals Co's Ending Cash Position for the quarter that ended in Mar. 2025 was ¥1,416 Mil.

Shenzhenlubris Pharmaceuticals Co's quarterly Ending Cash Position increased from Sep. 2024 (¥1,024 Mil) to Dec. 2024 (¥1,105 Mil) and increased from Dec. 2024 (¥1,105 Mil) to Mar. 2025 (¥1,416 Mil).

Shenzhenlubris Pharmaceuticals Co's annual Ending Cash Position declined from Dec. 2022 (¥2,551 Mil) to Dec. 2023 (¥1,318 Mil) and declined from Dec. 2023 (¥1,318 Mil) to Dec. 2024 (¥1,105 Mil).

Shenzhenlubris Pharmaceuticals Co Ending Cash Position Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Ending Cash Position Chart

Shenzhenlubris Pharmaceuticals Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

865.14

3,222.02

2,550.98

1,318.16

1,104.66

Shenzhenlubris Pharmaceuticals Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															1,408.53	936.11	1,024.30	1,104.66	1,416.04

Shenzhenlubris Pharmaceuticals Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shenzhenlubris Pharmaceuticals Co's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1318.161	+	-213.506
	=	1,105

Shenzhenlubris Pharmaceuticals Co's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1104.655	+	311.38
	=	1,416

Shenzhenlubris Pharmaceuticals Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhenlubris Pharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6009 Shennan Road, 37th Floor, Main Building, Chegongmiao Lvjing Plaza, Futian District, Guangdong, Shenzhen, CHN, 518040

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co Headlines

No Headlines